

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



03-18-04

PC019090B/AG0136-02

PC019090B/AG0136-02
REQUEST FOR CORRECTED FILING RECEIPT

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (#EV 291841808 US) in an envelope addressed to: Mail Stop: Application Number, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 16th day of March 2004.

s/ Pamela Hollander
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
David John KUCERA et al.

Serial No.: 10/728,602

Filed: December 4, 2003

For: HIV PROTEASE INHIBITORS,
COMPOSITIONS CONTAINING THE SAME,
THEIR PHARMACEUTICAL USES AND
MATERIALS FOR THEIR SYNTHESIS

Group Art Unit: 1626

Examiner: Not Yet Assigned

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop Application Number
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please make the following corrections to the filing receipt and kindly generate another Filing Receipt incorporating the requested corrections:

--Please change the FILING OR 371(c) DATE to 12/04/2003--

The above-identified application was deposited in Express Mail with the United States Postal Service on December 4, 2003, as evidenced by an enclosed copy of the official receipt bearing a December 4, 2003 date stamp. In addition, a copy of the Transmittal Letter is enclosed in which Pamela Hollander certifies that the papers were deposited in Express Mail with the United States Postal Service on December 4, 2003.

As such, Applicants believe they are entitled to a filing date for the above-identified application of **December 4, 2003**.



No fee is believed to be due at this time. If the applicant is in error, please charge all fees related to this filing to Deposit Account No. 500329.

Respectfully submitted,

Date: March 16, 2004


Jeffrey M. Tidwell
Attorney For Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233



Filed in the U.S. Patent and Trademark Office via Express Mail No. EV 34107997 US

Attorney Docket No.: PC19090B / AG0136-02

U.S. Patent Application Serial No. To be Assigned Filed: To be Assigned Confirmation # To be Assigned

In Re Application of: David John KUCERA

Title: HIV Protease Inhibitors, Compositions Containing the Same, Their Pharmaceutical Uses and Materials for their Synthesis

Please date stamp and return this postage-prepaid card to applicant to show receipt of the following enclosures:

Transmittal Letter	1 page;
Application Data Sheet	2 pages;
Utility Patent Application Transmittal	1 page;
Specification	228 pages;
Claims	6 pages;
Abstract	1 page; and
Fee Transmittal	1 page (+ duplicate).

Date: December 4, 2003

Responsible Atty: Jeffrey H. Tidwell

Filed in the U.S. Patent and Trademark Office via Express Mail No. EV 34107997 US

Attorney Docket No.: PC19090B / AG0136-02

U.S. Patent Application Serial No. To be Assigned Filed: To be Assigned Confirmation # To be Assigned

In Re Application of: David John KUCERA

Title: HIV Protease Inhibitors, Compositions Containing the Same, Their Pharmaceutical Uses and Materials for their Synthesis

Please date stamp and return this postage-prepaid card to applicant to show receipt of the following enclosures:

Transmittal Letter	1 page;
Application Data Sheet	2 pages;
Utility Patent Application Transmittal	1 page;
Specification	228 pages;
Claims	6 pages;
Abstract	1 page; and
Fee Transmittal	1 page (+ duplicate).

RECEIVED

DEC 18 2003

Date: December 4, 2003

Responsible Atty: Jeffrey H. Tidwell

LA JOLLA PATENT DEPT

315342 U.S. PTO
10/728602



120503



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as **Express Mail (EV 34107997 US)** in an envelope addressed to: Mail Stop: Patent Applications Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 4th day of December 2003.

s/ Pamela Hollander
Pamela Hollander, M.A.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
David John KUCERA, et al.

Serial No.: To be Assigned

Filed: Herewith

For: HIV Protease Inhibitors, Compositions
Containing the Same, Their Pharmaceutical
Uses and Materials for their Synthesis

Group Art Unit: To be Assigned

Examiner: To be Assigned

Mail Stop: Patent Applications
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

Return Receipt Postcard
Application Data Sheet
Utility Patent Application Transmittal
Specification
Claims
Abstract
Fee Transmittal


1 page;
2 pages;
1 page;
228 pages;
6 pages;
1 page; and
1 page (+ duplicate).

Respectfully submitted,

Date: December 4, 2003

Jeffrey H. Tidwell
Jeffrey H. Tidwell
Attorney For Applicants
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

Attorney Docket No.

PC019090B / AG 0136 - 02

First Inventor

David John Kucera

Title

HIV Protease Inhibitors, Compositions
Containing the Same, Their
Pharmaceutical Uses, Material for Their
Synthesis

Express Mail Label No.

EV 341079927 US

(Only for new nonapplications under 37C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Applications
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. ☐ Applicant claims small entity status
See 37 CFR 1.27

3. ☒ Specification [Total Pages **235**]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the invention
 - Brief Summary of the invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. ☐ Drawing(s) (35 U.S.C. 113) [Total sheets _____]

5. ☐ Oath or Declaration [Total pages _____]

- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or
computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy (CRF)

- b. Specification Sequence Listing on:

- i. ☐ CD-ROM or CD-R (2 copies)

- ii. ☐ Paper

- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. 10/166,957

Prior application information: Examiner Group/Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

19. CORRESPONDENCE ADDRESS☒ Customer Number

28940

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

NAME (Print/type)

Jeffery H. Tidwell

Registration No. (Attorney/Agent)

47,995

Signature

Date

December 4, 2003



FEE TRANSMITTAL for FY 2004				Complete if Known			
Effective 10/01/2003. Patent fees are subject to annual revision.				Application Number			
<input type="checkbox"/> Applicant claims small status. See 37 CFR 1.27				To be Assigned			
Total Amount of Payment \$942.00				Filing Date			
METHOD OF PAYMENT (check all that apply)				December 4, 2003			
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None				First Named Inventor			
<input checked="" type="checkbox"/> Deposit Account:				David John Kucera			
Deposit Account Number: 500329				Examiner Name			
Deposit Account Name: Pfizer Inc				To be Determined			
The Director is authorized to: (check all that apply)				Art Unit			
<input type="checkbox"/> Charge fee(s) indicated below <input type="checkbox"/> Credit any overpayments				To be Determined			
<input checked="" type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s)				Attorney Docket No.			
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.				PC019090B / AG 0136 - 02			
FEE CALCULATION				FEE CALCULATION (continued)			
1. BASIC FILING FEE				3. ADDITIONAL FEES			
Large Entity Small Entity				Large Entity Small Entity			
Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee Paid				Fee Code Fee (\$) Fee Code Fee (\$) Fee Description Fee Paid			
1001 770 2001 385 Utility filing fee 770				1051 130 2051 65 Surcharge - late fee or oath			
1002 340 2002 170 Design filing fee				1052 50 2052 25 Surcharge-late filing fee or cover sheet			
1003 530 2203 265 Plant filing fee				1053 130 1053 130 Non-English specification			
1004 770 2004 385 Reissue filing fee				1812 2,520 1812 2,520 For filing a request for Ex Parte reexamination			
1005 160 2005 80 filing fee				1804 920* 1804 920* Requesting publication of SIR prior to Examiner action			
Subtotal (1)s \$ 770				1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE				1251 110 2251 55 Extension for reply within first month			
Extra Claims Fee from below Fee Paid				1252 420 2252 210 Extension for reply within second month			
Total Claims 18 - 20** = 0 x 0 = 0				1253 950 2253 475 Extension for reply within third month			
Independent Claims 5 - 3 = 2 x 86 = 172				1254 1,480 2254 740 Extension for reply within fourth month			
Multiple Dependent				1255 2,010 2255 1,005 Extension for reply within fifth month			
Large Entity Small Entity				1401 330 2401 165 Notice of Appeal			
Fee Code Fee (\$) Fee Code Fee (\$) Fee Description				1402 330 2402 165 Filing a brief in support of an appeal			
1202 18 2202 9 Claims in excess of 20				1403 290 2403 145 Request for oral hearing			
1201 86 2201 43 Independent claims in excess of 3				1451 1,510 1451 1,510 Petition to institute a public use proceeding			
1203 290 2203 145 Multiple dependent claim, if not paid				1452 110 2452 55 Petition to revive unavoidable			
1204 86 2204 43 **Reissue independent claims over original patent				1453 1,330 2453 665 Petition to revive - unintentional			
1205 18 2205 9 **Reissue independent claims over original patent				1501 1,330 2501 685 Utility issue fee (or reissue)			
(\$ 942)				1502 480 2502 240 Design issue fee			
**or number previously paid, if greater. For Reissues, see above				1503 640 2503 320 Plant issue fee			
SUBMITTED BY				1460 130 1460 130 Petitions to the Commissioner			
Name (Printed/Type) Jeffrey H. Tidwell				1807 50 1807 50 Processing fee under 37 CFR 1.17(q)			
Registration No. 47,995				1806 180 1806 180 Submission of Information Disclosure Stmt			
Telephone 858.638.3877				8021 40 8021 40 Recording each patent assignment per property (times number of properties)			
Signature				1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))			
				1810 770 2810 385 For each additional invention to be examined (37 CFR 1.129(b))			
				1801 770 2801 385 Request for Continued Examination (RCE)			
				1802 900 1802 900 Request for expedited examination of a design application			
				Other Fee (specify)			
				Subtotal (3) (\$)			
				*Reduced by Basic Filing Fee Paid			

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.